ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma

Yu, Sheng; Tang, Lingxue; Zhang, Qianqian; Li, Wen; Yao, Senbang; Cai, Yinlian; Cheng, Huaidong*安徽医科大学; 南方医科大学
HEREDITAS2023-7-24DOI: 10.1186/s41065-023-00293-w
2被引11阅读
引用收藏
分享

摘要

BackgroundCopper-induced cell death (cuproptosis) is a new regulatory cell death mechanism. Long noncoding RNAs (lncRNAs) are related to tumor immunity and metastasis. However, the correlation of cuproptosis-related lncRNAs with the immunotherapy response and prognosis of lung adenocarcinoma (LUAD) patients is not clear.MethodsWe obtained the clinical characteristics and transcriptome data from TCGA-LUAD dataset (containing 539 LUAD and 59 paracancerous tissues). By utilizing LASSO-penalized Cox regression analysis, we identified a prognostic signature composed of cuproptosis-related lncRNAs. This signature was then utilized to segregate patients into two different risk categories based on their respective risk scores. The identification of differentially expressed genes (DEGs) between high- and low-risk groups was carried out using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. We evaluated the immunotherapy response by analyzing tumor mutational burden (TMB), immunocyte infiltration and Tumor Immune Dysfunction and Exclusion (TIDE) web application. The "pRRophetic" R package was utilized to conduct further screening of potential therapeutic drugs for their sensitivity.ResultsWe ultimately identified a prognostic risk signature that includes six cuproptosis-related lncRNAs (AP003778.1, AC011611.2, CRNDE, AL162632.3, LY86-AS1, and AC090948.1). Compared with clinical characteristics, the signature was significantly correlated with prognosis following the control of confounding variables (HR = 2.287, 95% CI = 1.648-3.174, p < 0.001), and correctly predicted 1-, 2-, and 3-year overall survival (OS) rates (AUC value = 0.725, 0.715, and 0.662, respectively) in LUAD patients. In terms of prognosis, patients categorized as low risk exhibited more positive results in comparison to those in the high-risk group. The enrichment analysis showed that the two groups had different immune signaling pathways. Immunotherapy may offer a more appropriate treatment option for high-risk patients due to their higher TMB and lower TIDE scores. The higher risk score may demonstrate increased sensitivity to bexarotene, cisplatin, epothilone B, and vinorelbine.ConclusionsBased on cuproptosis-related lncRNAs, we constructed and validated a novel risk signature that may be used to predict immunotherapy efficacy and prognosis in LUAD patients.

学科与关键词

关键词
Lung adenocarcinomaNon-small cell lung cancer (NSCLC)CuproptosisLncRNAsPrognostic signatureImmunotherapy response
相关
加载中…
  • Identification of cuproptosis-related gene signature to predict prognosis in lung adenocarcinoma
    Lv, Yanju; Xiao, Yajie; Cui, Xiaoli; Luo, Haitao*; Xu, Long*Frontiers in Genetics, 2022, 13: 1016871.被引 3
  • Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients
    Jiang, Zi-Rong; Yang, Lin-Hui; Jin, Liang-Zi; Yi, Li-Mu; Bing, Ping-Ping; Zhou, Jun*; Yang, Jia-Sheng*Frontiers in Oncology, 2022, 12: 988680.被引 25
  • Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC
    Wang, Yu; Xiao, Xu; Li, Yan*Scientific Reports, 2023, 13(1): 2477.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
HEREDITAS
发表日期
2023-07-24
卷期
第 160 卷, 第 1 期
页码
31
DOI
10.1186/s41065-023-00293-w
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81872504]

作者

  • Y

    Yu, Sheng (第一作者)

    2 · anhui med univ · southern med univ

  • T

    Tang, Lingxue

    2 · anhui med univ

查看全部 7 位作者收起作者
  • Z

    Zhang, Qianqian

    2 · anhui med univ

  • L

    Li, Wen

    2 · anhui med univ

  • Y

    Yao, Senbang

    2 · anhui med univ

  • C

    Cai, Yinlian

    2 · anhui med univ

  • C

    Cheng, Huaidong (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417